CSL Seqirus
56 articles about CSL Seqirus
-
Seqirus Presents New Real-World Evidence Demonstrating Effectiveness of Cell-Based and Adjuvanted Seasonal Influenza Vaccines at IDWeek 2021
9/29/2021
Seqirus today announced data supporting the effectiveness of both cell-based and adjuvanted seasonal influenza vaccines from two real-world studies conducted during the 2019/2020 influenza season in the U.S.
-
COVID-19 Booster Shots, the Flu and You
8/23/2021
While last flu season saw fears of a “twindemic” go largely unfounded, there are fears that recent lockdowns could also lead to a lack of natural immunity against the flu. -
Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)
8/19/2021
Seqirus today announced plans to accelerate the development of its next generation of messenger RNA (mRNA) vaccine technology
-
New Jersey-based Seqirus is expanding and accelerating its capabilities to develop next-generation self-amplifying mRNA (sa-mRNA) vaccines for influenza and other viral illnesses.
-
Seqirus Presents New Real-World Evidence on Relative Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older at IDWeek 2020
10/21/2020
Seqirus, a global leader in influenza prevention, today presented new real-world evidence (RWE) on the effectiveness of an MF59 ® -adjuvanted, trivalent seasonal influenza vaccine (aTIV) in adults 65 years and older during the 2018/19 U.S. influenza season at the IDWeek 2020 virtual conference. 1 aTIV was found to be more effecti
-
Seqirus snagged approval for Fluad Quadrivalent, the first-and-only quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.
-
Audenz is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A (H5N1) in the event of a pandemic.
-
Seqirus Announces U.S. FDA Approval of Its First-Ever Adjuvanted, Cell-Based Pandemic Influenza A (H5N1) Vaccine
2/3/2020
Seqirus announced that the U.S. Food and Drug Administration has approved AUDENZ™ Monovalent Vaccine, Adjuvanted) to help protect individuals six months of age and older against influenza A.1 AUDENZ is the first-ever adjuvanted, cell-based influenza vaccine designed to protect against influenza A in the event of a pandemic.
-
Clinical Catch-Up: December 9-13
12/16/2019
It was a particularly busy week in clinical trial news, largely because of the American Society of Hematology Annual Meeting. Here’s a look. -
Seqirus released new data that shows Fluad, an adjuvanted trivalent influenza vaccine, was more effective than standard non-adjuvanted trivalent influenza vaccine in reducing the risk of flu- and pneumonia-related hospitalization in patients 65-years-of-age and older.
-
Seqirus Applauds the Executive Order to Accelerate Enhanced Protection Against Influenza Threats
9/26/2019
Seqirus, a leading innovator in influenza vaccines and pandemic preparedness, applauds the Administration for recognizing the urgency of ensuring Americans are better protected against seasonal and pandemic influenza threats by releasing the Executive Order on Modernizing Influenza Vaccines in the United States to Promote National Security and Public Health.
-
Seqirus Presents New Scientific Data Comparing Circulating Influenza B Viruses With Both Cell-Based and Egg-Based Influenza B Reference Viruses
8/31/2019
Seqirus presented new scientific data at the Options for the Control of Influenza Conference in Singapore that demonstrated circulating influenza B/Victoria viruses are a closer match to cell-based B/Vic vaccine viruses compared with egg-based B/Vic vaccine viruses.
-
Seqirus Announces Further Advances in Cell-Based Influenza Vaccine Technology
4/15/2019
This decision makes the entire production process exclusively cell-based.
-
Seqirus, a wholly owned subsidiary of CSL, is expanding its manufacturing plant in North Carolina. It expects to invest $140 million in the expansion.
-
Seqirus Releases Real-World Data Indicating Significantly Greater Effectiveness of Cell-Based Seasonal Influenza Vaccines Compared to Standard Influenza Vaccine Options
11/16/2018
Seqirus, a global leader in influenza prevention, today released a new real-world evidence analysis indicating that its cell-based quadrivalent influenza vaccine (QIVc) was 36.2 percent more effective than standard egg-based quadrivalent vaccine (QIVe) in preventing influenza-like illness
-
Seqirus Announces U.S. $140 Million Manufacturing Expansion to Meet Growing Demand for Innovative Cell-Based Influenza Vaccines
11/16/2018
Seqirus, a wholly owned subsidiary of CSL Limited and a global leader in influenza prevention, today announced a $140M expansion of its Holly Springs manufacturing facility in North Carolina.
-
Seqirus Receives FDA Approval of AFLURIA® QUADRIVALENT (Influenza Vaccine) for People Six Months of Age and Older in the U.S.
10/23/2018
Seqirus today announced the U.S. Food and Drug Administration (FDA) has approved AFLURIA® QUADRIVALENT (Influenza Vaccine) for use in people six months of age and older,1 extending the company's broad portfolio of influenza vaccine offerings. The approval also applies to the trivalent formulation of AFLURIA® (Influenza Vaccine).2
-
Seqirus Presents Favorable Outcomes Data for Adjuvanted Trivalent Influenza Vaccine (FLUAD®) at 6th Annual IDWeek
10/3/2018
New studies highlight health and economic benefits of adjuvanted trivalent influenza vaccine amongst two at-risk populations - 65 years+ and young children
-
Seqirus Presents Data at IDWeek Demonstrating Cell-Derived Viruses Have a Closer Match to Circulating Influenza Viruses Compared to Egg-derived Viruses Used in the Production of Influenza Vaccines
10/3/2018
Seqirus today announced data, to be presented at IDWeek 2018 on Saturday, October 6, showing that higher levels of mismatch have consistently occurred with egg-derived influenza vaccine viruses compared with cell-derived vaccine viruses.
-
Seqirus secures FDA approval for next generation cell-based influenza vaccine manufacturing process
8/23/2018
Seqirus today announced FDA approval of its next generation cell-based manufacturing process at Holly Springs, North Carolina.